Pioglitazone Ameliorates Intracerebral Insulin Resistance and Tau-protein Hyperphosphorylation in Rats with Type 2 Diabetes

Abstract

Objective:

To investigate intracerebral insulin resistance and its relationship with tau-protein hyperphosphorylation.

Methods:

A rat model of type 2 diabetes (T2D) was established with streptozotocin (STZ). Diabetic rats received intragastric administration of pioglitazone (PIO group) or normal saline (T2D group) for 4 weeks. As a control, non-diabetic rats received intragastric normal saline (CTL group). The insulin concentrations in cerebrospinal fluid (CSF) and blood were determined with radioimmunoassay, and blood glucose concentration was determined using a glucose oxidation technique. Total and phosphorylated levels of protein kinase B (AKT), glycogen synthase kinase-3β (GSK-3β) and tau-protein in the hippocampus were analyzed using western blotting.

Results:

The plasma insulin level in the T2D group was higher, and the CSF insulin level in the T2D group lower than in the CTL group. Hippocampal phosphorylated AKT and phosphorylated GSK-3β levels were significantly lower in the T2D group than in the CTL group. Hippocampal tau-protein in the T2D group was hyperphosphorylated at Ser199 and Ser396. Plasma insulin levels in the PIO group were lower than in the T2D group, with no differences in CSF insulin levels. Phosphorylated AKT and phosphorylated GSK-3β levels in the PIO group were significantly higher than in the T2D group. Hippocampal phosphorylated tau-protein (Ser199/Ser396) was lower in the PIO group than in the T2D group.

Conclusion:

Hyperphosphorylation of tau-protein in pioglitazone-treated rats with T2D was improved. Rats with T2D have both cerebral insulin resistance and cerebral hypoinsulinism. Pioglitazone can ameliorate intracerebral insulin resistance and decrease tau-protein hyperphosphorylation, but cannot increase intracerebral insulin levels.

Key words

Alzheimer’s disease - dementia - glucose metabolism - anti-diabetic drug

• References

• 1 Yang W, Lu J, Weng J et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362: 1090-1101
• 2 Alzheimer’s Association . 2010; 2010 Alzheimer’s disease facts and figures. Alzheimers Dement 2010; 6: 158-194
• 3 Arvanitakis Z, Wilson RS, Bienias JL et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61: 661-666
• 4 Xu WL, Qiu CX, Wahlin A et al. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004; 63: 1181-1186
• 5 de la Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer’s disease. Drugs 2012; 72: 49-66
• 6 Plaschke K, Kopitz J, Siegelin M et al. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J Alzheimers Dis 2010; 19: 691-704
• 7 Belgardt BF, Bruning JC. CNS leptin and insulin action in the control of energy homeostasis. Ann N Y Acad Sci 2010; 1212: 97-113
• 8 Craft S, Peskind E, Schwartz MW et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998; 50: 164-168
• 9 Laron Z. Insulin and the brain. Arch Physiol Biochem 2009; 115: 112-116
• 10 Park CR, Seeley RJ, Craft S et al. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav 2000; 68: 509-514
• 11 Wang X, Zheng W, Xie JW et al. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener 2010; 5: 46
• 12 Talbot K, Wang HY, Kazi H et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122: 1316-1338
• 13 de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res 2012; 9: 35-66
• 14 Williamson R, McNeilly A, Sutherland C. Insulin resistance in the brain: an old-age or new-age problem?. Biochem Pharmacol 2012; 84: 737-745
• 15 Li X, Pan W, Yang GZ et al. Proteome analysis of differential protein expression in brain of rats with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011; 119: 265-270
• 16 Qian W, Shi J, Yin X et al. PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis 2010; 19: 1221-1229
• 17 Zhang XJ, Yang SS, Zhang MX. Common pathogenesis of type 2 diabetes and Alzheimer’s disease: a potential mechanism. Chin J Pathophysiol 2010; 26: 1107-1114
• 18 Sato T, Hanyu H, Hirao K et al. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011; 32: 1626-1633
• 19 Kanazawa I, Yamamoto M, Yamaguchi T et al. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011; 119: 362-365
• 20 Dorafshar AH, Moodley K, Khoe M et al. Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat. Diab Vasc Dis Res 2010; 7: 20-27
• 21 Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 1969; 6: 24-27
• 22 Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
• 23 Höistad M, Samskog J, Jacobsen KX et al. Detection of beta-endorphin in the cerebrospinal fluid after intrastriatal microinjection into the rat brain. Brain Res 2005; 1041: 167-180
• 24 Leavens KF, Birnbaum MJ. Insulin signaling to hepatic lipid metabolism in health and disease. Crit Rev Biochem Mol Biol 2011; 46: 200-215
• 25 Hu SH, Yang Y, Ai DY. Tau protein phosphorylation levels and glycogen synthase kinase-3β activities were increased in hippocampus of rats with type 1 or type 2 diabetes. Basic Clinic Med 2007; 27: 1001-1005
• 26 Panunti B, Fonseca V. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients. Vascul Pharmacol 2006; 45: 29-35
• 27 Srinivasan K, Patole PS, Kaul CL et al. Reversal of glucose intolerance by by pioglitazone in high fat diet-fed rats. Methods Find Exp Clin Pharmacol 2004; 26: 327-333
• 28 Teramoto T, Yamada N, Shirai K et al. Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus. J Atheroscler Thromb 2007; 14: 86-93
• 29 Pavo I, Jermendy G, Varkonyi TT et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 1637-1645
• 30 Kubo K. Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. Endocr J 2002; 49: 323-328